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Benefit v. risk when using chloroquine 
in patients with severe COVID-19 
disease
To the Editor: Chloroquine (CQ) is widely advocated as treatment 
for coronavirus disease 2019 (COVID-19), including the president of 
the USA publicly supporting the use of hydroxychloroquine (HCQ) 
as a ‘game-changer’ on the social media platform Twitter. CQ and 
HCQ are structurally similar, with HCQ having an N-hydroxyl-ethyl 
side-chain in place of the N-diethyl group.[1] Currently only CQ is 
being marketed in South Africa. We encourage the development of 
curative directed therapy against severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) using appropriate designed trials and 
regulatory oversight, and caution against the indiscriminate use of 
CQ or HCQ. Careful patient selection is essential, including assessing 
prognosis, anticipated benefit and potential harms prior to initiating 
CQ/HCQ therapy. 
The benefit of CQ/HCQ is not yet clearly defined. CQ/HCQ 
demonstrated in vitro antiviral activity against SARS-CoV-2.[2,3] 
Although the antiviral mechanisms of CQ/HCQ are still being 
investigated, a number of mechanisms have been proposed. CQ/
HCQ inhibits autophagy by impairing membrane fusion of SARS-
CoV-2 with intracellular endosomes or lysosomes, perhaps by 
increasing the pH of these organelles;[4] interferes with glycosylation 
intracellular receptors (angiotensin-converting enzyme 2);[5,6] or 
inhibits T-cell-mediated proinflammatory cytokines implicated in 
acute respiratory distress syndrome.[7] In vivo evidence is currently 
limited but increasing with multiple ongoing studies. A small French 
open-label non-randomised controlled trial of 26 patients diagnosed 
with COVID-19 receiving HCQ is widely cited.[8] Of the 26 patients, 
only 20 were included in the analysis; 6 were receiving concomitant 
azithromycin for bacterial infections. Sixteen control patients were 
included. Viral clearance on nasopharyngeal swabs was greater 
at day 6 in HCQ and greatest in the 6 HCQ plus azithromycin-
treated patients. Although promising, the study suffered from many 
limitations, as outlined by Dahly et al.[9] 
Others have argued that our understanding of the SARS-CoV-2 
pathophysiology is incomplete and that the immune effects of CQ/
HCQ are unknown.[10] CQ had a paradoxical effect, where the 
decrease in cytokines delayed the adaptive immune response with 
worsened disease in a primate study with Chikungunya virus. [11] 
Although CQ and HCQ have been used safely for decades to 
treat outpatients with rheumatic diseases and malaria, critically ill 
patients with severe SARS-CoV-2 disease and immune dysregulation 
may be at higher risk of CQ/HCQ toxicity. The toxic dose of 
CQ and HCQ is close to the therapeutic range.[12,13] CQ/HCQ 
cardiotoxicity includes dysrhythmias, depressed cardiac contractility 
and conduction associated with hypokalaemia due to potassium 
shifting. Renal and hepatic impairment may increase CQ/HCQ 
concentrations, as CQ and HCQ are renally eliminated and hepatically 
metabolised.[14] Underlying cardiac disease or cardiac risk factors, 
concomitant QT-prolonging medicines and enzyme inhibitors may 
therefore increase the risk of CQ/HCQ toxicity. Investigational 
therapy, treatment or prophylaxis, with unknown benefit v. harm, 
is best studied as part of a clinical trial with appropriate ethical and 
regulatory oversight. Lastly, CQ stock is limited worldwide, and CQ 
is an essential medicine to treat systemic lupus erythematosus (SLE). 
Stock prioritisation away from these patients may lead to acute disease 
flare-ups, which could add additional pressure to the health system 
and unnecessarily expose SLE patients to the hospital environment. 
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